Synlogic (SYBX) Competitors $1.59 -0.08 (-4.79%) Closing price 07/25/2025 03:59 PM EasternExtended Trading$1.61 +0.02 (+1.51%) As of 07/25/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. ADVM, PDSB, ANVS, ANL, GANX, NRXP, ATRA, KRON, CELU, and VTVTShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Adverum Biotechnologies (ADVM), PDS Biotechnology (PDSB), Annovis Bio (ANVS), Adlai Nortye (ANL), Gain Therapeutics (GANX), NRx Pharmaceuticals (NRXP), Atara Biotherapeutics (ATRA), Kronos Bio (KRON), Celularity (CELU), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Its Competitors Adverum Biotechnologies PDS Biotechnology Annovis Bio Adlai Nortye Gain Therapeutics NRx Pharmaceuticals Atara Biotherapeutics Kronos Bio Celularity vTv Therapeutics Adverum Biotechnologies (NASDAQ:ADVM) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Do analysts recommend ADVM or SYBX? Adverum Biotechnologies currently has a consensus target price of $23.80, suggesting a potential upside of 781.48%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe Adverum Biotechnologies is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in ADVM or SYBX? 48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 6.0% of Adverum Biotechnologies shares are owned by insiders. Comparatively, 3.0% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to ADVM or SYBX? In the previous week, Adverum Biotechnologies had 2 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Adverum Biotechnologies and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.89 beat Adverum Biotechnologies' score of 1.56 indicating that Synlogic is being referred to more favorably in the news media. Company Overall Sentiment Adverum Biotechnologies Very Positive Synlogic Very Positive Is ADVM or SYBX more profitable? Synlogic's return on equity of 10.91% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adverum BiotechnologiesN/A -130.53% -66.31% Synlogic N/A 10.91%7.47% Which has better earnings & valuation, ADVM or SYBX? Synlogic has lower revenue, but higher earnings than Adverum Biotechnologies. Synlogic is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdverum Biotechnologies$1M56.40-$130.93M-$6.40-0.42Synlogic$10K1,860.30-$23.36M-$2.51-0.63 Which has more volatility and risk, ADVM or SYBX? Adverum Biotechnologies has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. SummaryAdverum Biotechnologies beats Synlogic on 8 of the 15 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.53M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-0.6321.1828.1020.05Price / Sales1,860.30288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book1.468.378.665.87Net Income-$23.36M-$55.19M$3.25B$258.55M7 Day Performance-8.62%5.88%4.23%3.74%1 Month Performance30.33%17.33%10.52%11.75%1 Year Performance-4.79%4.42%34.41%18.03% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic1.3093 of 5 stars$1.59-4.8%N/A-5.4%$19.53M$10K-0.6380Positive NewsGap UpADVMAdverum Biotechnologies4.5009 of 5 stars$2.73+7.5%$23.80+771.8%-66.6%$57.03M$1M-0.43190News CoveragePositive NewsPDSBPDS Biotechnology1.2455 of 5 stars$1.23-0.8%$9.00+631.7%-70.1%$56.22MN/A-1.3120ANVSAnnovis Bio1.8523 of 5 stars$2.87+5.7%$18.00+528.3%-72.1%$55.84MN/A-1.333ANLAdlai Nortye1.897 of 5 stars$1.51-6.2%$9.00+496.0%-57.6%$55.72M$5M0.00127GANXGain Therapeutics2.3564 of 5 stars$1.86+7.5%$8.20+340.9%+62.5%$55.71M$50K-2.1620Gap UpNRXPNRx Pharmaceuticals2.5358 of 5 stars$3.21flat$28.50+787.9%+28.2%$55.50MN/A-1.602ATRAAtara Biotherapeutics4.6337 of 5 stars$9.30+0.8%$17.75+90.9%+18.6%$55.44M$199.73M-2.50330News CoveragePositive NewsKRONKronos BioN/A$0.88+1.5%$1.63+84.7%-34.3%$53.72M$9.85M-0.82100CELUCelularity0.1409 of 5 stars$2.24+6.2%N/A-1.0%$53.65M$54.22M-0.85220News CoverageUpcoming EarningsVTVTvTv Therapeutics1.54 of 5 stars$16.71-1.8%$35.50+112.4%-26.6%$53.31M$1.02M-5.559News CoveragePositive News Related Companies and Tools Related Companies Adverum Biotechnologies Competitors PDS Biotechnology Competitors Annovis Bio Competitors Adlai Nortye Competitors Gain Therapeutics Competitors NRx Pharmaceuticals Competitors Atara Biotherapeutics Competitors Kronos Bio Competitors Celularity Competitors vTv Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYBX Stock Alerts